ENLV Enlivex Therapeutics Ltd

Price (delayed)

$1.215

Market cap

$19.23M

P/E Ratio

0

Dividend/share

N/A

EPS

$406

Enterprise value

$13.86M

?
Relative Growth: Rel. Growth: 38
Relative Strength: Rel. Strength: 0
Relative Valuation: Rel. Valuation: 94
Relative Profitability: Rel. Profitability: 64

Bio Blast Pharma Ltd., a development stage biopharmaceutical company, focuses on the identification, licensing, acquisition, development, and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. The company ...

Highlights
ENLV's debt is up by 28% YoY

Key stats

What are the main financial stats of ENLV

ENLV stock price

How has the Enlivex Therapeutics stock price performed over time
Intraday
-10%
1 week
-19.54%
1 month
-41.87%
1 year
-92.29%
YTD
-88.48%
QTD
-85.27%

Financial performance

How have Enlivex Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$15.03M
Net income
$1.24B
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 5% YoY

Price vs fundamentals

How does ENLV's price correlate with its fundamentals

Growth

What is Enlivex Therapeutics's growth rate over time

Valuation

What is Enlivex Therapeutics stock price valuation
P/E
0
P/B
0
P/S
N/A
EV/EBIT
0.01
EV/EBITDA
0.01
EV/Sales
N/A
ENLV's P/B is 100% below its 5-year quarterly average of 1.3 and 100% below its last 4 quarters average of 1.0

Efficiency

How efficient is Enlivex Therapeutics business performance
The ROIC has soared by 148% YoY and by 103% from the previous quarter

Dividends

What is ENLV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENLV.

Financial health

How did Enlivex Therapeutics financials performed over time
ENLV's debt is 100% lower than its equity
The debt to equity has plunged by 100% YoY
ENLV's debt is up by 28% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.